These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 11790159)
41. Impact of medical treatments for benign prostatic hyperplasia on sexual function. Giuliano F BJU Int; 2006 Apr; 97 Suppl 2():34-8; discussion 44-5. PubMed ID: 16507052 [TBL] [Abstract][Full Text] [Related]
42. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride. Zlotta AR; Teillac P; Raynaud JP; Schulman CC Eur Urol; 2005 Aug; 48(2):269-76. PubMed ID: 15939527 [TBL] [Abstract][Full Text] [Related]
43. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia. Tsujii T Int J Urol; 2000 Jun; 7(6):199-205. PubMed ID: 10843450 [TBL] [Abstract][Full Text] [Related]
44. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818 [TBL] [Abstract][Full Text] [Related]
45. Tamsulosin: real life clinical experience in 19,365 patients. Michel MC; Bressel HU; Mehlburger L; Goepel M Eur Urol; 1998; 34 Suppl 2():37-45. PubMed ID: 9732827 [TBL] [Abstract][Full Text] [Related]
46. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. Okada H; Kamidono S; Yoshioka T; Okuyama A; Ozono S; Hirao Y; Okajima E; Yamamoto K; Kishimoto T; Park Y; Kurita T BJU Int; 2000 Apr; 85(6):676-81. PubMed ID: 10759664 [TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia. Milicevic S; Bijelic R Med Arch; 2012; 66(3):173-6. PubMed ID: 22822617 [TBL] [Abstract][Full Text] [Related]
48. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659 [TBL] [Abstract][Full Text] [Related]
49. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. de Mey C; Michel MC; McEwen J; Moreland T Eur Urol; 1998; 33(5):481-8. PubMed ID: 9643668 [TBL] [Abstract][Full Text] [Related]
50. Temporary intraurethral prostatic bridge-catheter compared with neoadjuvant and adjuvant alpha-blockade to improve early results of high-energy transurethral microwave thermotherapy. Djavan B; Ghawidel K; Basharkhah A; Hruby S; Bursa B; Marberger M Urology; 1999 Jul; 54(1):73-80. PubMed ID: 10414730 [TBL] [Abstract][Full Text] [Related]
51. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Lepor H Urology; 1998 Jun; 51(6):901-6. PubMed ID: 9609624 [TBL] [Abstract][Full Text] [Related]
52. Our experience with the treatment of benign prostatic hyperplasia (BPH) with tamsulosin. Cervenakov I; Fillo J Bratisl Lek Listy; 2001; 102(3):138-41. PubMed ID: 11433602 [TBL] [Abstract][Full Text] [Related]
53. The use of alpha-adrenoceptor antagonists in lower urinary tract disease. Chess-Williams R Expert Opin Pharmacother; 2002 Feb; 3(2):167-72. PubMed ID: 11829730 [TBL] [Abstract][Full Text] [Related]
54. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Singh DV; Mete UK; Mandal AK; Singh SK J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272 [TBL] [Abstract][Full Text] [Related]
56. Tamsulosin in the treatment of LUTS/BPH: an Italian multicentre trial. Muzzonigro G Arch Ital Urol Androl; 2005 Mar; 77(1):13-7. PubMed ID: 15906783 [TBL] [Abstract][Full Text] [Related]
57. Initial choices and final outcomes in lower urinary tract symptoms. Speakman MJ Eur Urol; 2001; 40 Suppl 4():21-30. PubMed ID: 11786676 [TBL] [Abstract][Full Text] [Related]
58. Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report. Palacio A; Hernández C; Marqués A; Prats J; Espinosa FJ Arch Esp Urol; 2004 May; 57(4):451-60. PubMed ID: 15270291 [TBL] [Abstract][Full Text] [Related]
59. Tamsulosin: effect on quality of life in 2740 patients with lower urinary tract symptoms managed in real-life practice in Spain. Batista JE; Palacio A; Torrubia R; Hernández C; Vicente J; Resel L; Arch Esp Urol; 2002; 55(1):97-105. PubMed ID: 11957763 [TBL] [Abstract][Full Text] [Related]
60. Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient's quality of life. Djavan B Urology; 2003 Sep; 62(3 Suppl 1):6-14. PubMed ID: 12957195 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]